9 Meters Biopharma
NMTR
NMTR was delisted on the 25th of July, 2023.
6 hedge funds and large institutions have $134K invested in 9 Meters Biopharma in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
14% less funds holding
Funds holding: 7 → 6 (-1)
19% less capital invested
Capital invested by funds: $165K → $134K (-$31K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$58.8K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$17.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$300 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$28K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$22K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$4.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $47K | +$58.8K | +196 | New |
|
|
VKH
2
Virtu KCG Holdings
New York
| $26K | -$4.8K | -16 | -13% |
|
|
RJFSA
3
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| $26K | – | – | – |
|
4
Citadel Advisors
Miami,
Florida
| $20K | – | – | – |
|
|
5
Northern Trust
Chicago,
Illinois
| $14K | +$17.4K | +58 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $1K | +$300 | +1 | +50% |
|
|
7
Goldman Sachs
New York
| – | -$28K | -81 | Closed |
|
|
8
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$22K | -64 | Closed |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$3K | -10 | Closed |
|
NMTR Hedge Fund Activity: Q1 2017 in Review
6 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q1 2017, worth a combined $134K — down 19% from $165K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NMTR and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Vanguard Group, opening a new position worth an estimated $58.8K. The largest seller was Goldman Sachs, exiting entirely with an estimated $28K sold.
- 6 institutional investors held 9 Meters Biopharma (NMTR) as of Q1 2017, down from 7 in Q4 2016.
- Funds reported $134K of 9 Meters Biopharma stock for Q1 2017, down 19% quarter-over-quarter.
- 2 funds opened new 9 Meters Biopharma positions in Q1 2017 and 3 closed out, a net change of -1 holder.
- The largest 9 Meters Biopharma buyer in Q1 2017 was Vanguard Group, an estimated $58.8K added.
- The largest 9 Meters Biopharma seller in Q1 2017 was Goldman Sachs, an estimated $28K sold.
Based on aggregated 13F filings for Q1 2017.